Trials / Enrolling By Invitation
Enrolling By InvitationNCT07345858
Salivary Oxytocin as a Biomarker of Psychedelic Treatment
Salivary Oxytocin as a Biomarker of Psychedelic Assisted Psychotherapy in Patients With Major Depressive Disorder
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- University of Geneva, Switzerland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Conditions
Timeline
- Start date
- 2026-01-05
- Primary completion
- 2026-07-31
- Completion
- 2026-10-30
- First posted
- 2026-01-16
- Last updated
- 2026-01-16
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT07345858. Inclusion in this directory is not an endorsement.